US FDA approves Lilly's Mounjaro to reduce cardiovascular risk

Eli Lilly said the U.S. FDA approved Mounjaro to reduce the risk of major adverse cardiovascular events in high-risk adults with type 2 diabetes. This regulatory expansion strengthens Mounjaro’s clinical positioning and potential market opportunity, supporting a positive outlook for the franchise.